Study	Reason for exclusion
Adson 1981	Less than 50% aged 18 years or younger
Al‐Attar 1986	Not reporting on hepatic late adverse effects
Amylon 1997	Follow‐up duration unclear
Atay 2005	Not reporting on hepatic late adverse effects
Avet Loiseau 1991	Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Bacigalupo 1991	Not reporting on hepatic late adverse effects
Balcerska 2000	Follow‐up duration unclear
Bauditz 2007	Case series
Benesch 2001	Not reporting on hepatic late adverse effects according to our defined outcome measures: hepatitis virus infection
Berjian 1980	No childhood cancer survivors: adult patients >18 years
Berman 1980	Less than 50% aged 18 years or younger
Bernstein 1993	Not reporting on hepatic late adverse effects
Blum 2002	Not reporting on hepatic late adverse effects
Broxson 2005	Case series
Brunet 2001	Less than 50% aged 18 years or younger
Carter 1997	Cancer treatment unclear
Cassady 1979	Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Cavo 1998	No childhood cancer survivors: adult patients >18 years
Cesaro 1997	Liver function testing in hepatitis virus positive patients
Chao 1993	Less than 50% aged 18 years or younger
Cheng 2005	No childhood cancer survivors: adult patients >18 years
Cheuk 2008	Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Chou 1996	Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Christosova 2005	Case series
Claviez 1996	Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Colsky 1955	Case series
Condren 2005	Impossible to differentiate between patients with and without potentially high‐risk treatment for hepatic late adverse effects
Damon 2006	No childhood cancer survivors: adult patients >18 years
Deeg 1986	Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Dibenedetto 1994	Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Dunkel 1998	Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Dupuis‐Girod 1996	Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Evans 1980	Not reporting on hepatic late adverse effects
Evans 1982	Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Evans 1990	Less than 50% aged 18 years or younger
Evans 1993	Less than 50% aged 18 years or younger
Exelby 1975	Follow‐up duration unclear
Fabbri 1994	Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Farthing 1982	Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Fink 1993	Impossible to differentiate between patients with and without potentially high‐risk treatment for hepatic late adverse effects
Forbes 1995	Less than 50% aged 18 years or younger
Frickhofen 1994	Less than 50% aged 18 years or younger
Gandola 2009	Not reporting on hepatic late adverse effects
Ganjoo 2006	No childhood cancer survivors: adult patients >18 years
Glick 2000	Less than 10 childhood cancer survivors
Gluckman 1979	Unclear if one of our defined outcome measures was tested
Gonzalez‐Crussi 1982	Not reporting on hepatic late adverse effects
Greenfield 2006	Not reporting on hepatic late adverse effects
Grill 1996	Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Grosfeld 1976	Case series
Gutjahr 1980	Cancer treatment unclear
Haddy 1998	Liver function testing in hepatitis virus positive patients
Hadley 2002	Not reporting on hepatic late adverse effects
Halonen 2003	Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Hanks 1980	Not reporting on hepatic late adverse effects
Harrison 1996	Less than 50% aged 18 years or younger
Hatanaka 1994	No childhood cancer survivors: adult patients >18 years
Haupt 2004	Unclear if one of our defined outcome measures was tested
Hedrick 2004	Not reporting on hepatic late adverse effects
Hegewald 1982	Not reporting on hepatic late adverse effects according to our defined outcome measures; Unclear if case series or cohort study
Henderson 2008	Case report
Hjern 2007	Not reporting on hepatic late adverse effects
Ho 2004	No childhood cancer survivors: adult patients
Hollard 1980	Less than 50% aged 18 years or younger
Holschneider 1977	Not reporting on hepatic late adverse effects according to our defined outcome measures: hepatitis virus infection
Horowitz 1993	Not reporting on hepatic late adverse effects
Hutter 1960	Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Ingold 1965	Case series
Isaacs 2008	Not reporting on hepatic late adverse effects
Ivantes 2004	No childhood cancer survivors: adult patients
Jaffe 1975	Review
Jagannathan 2004	No childhood cancer survivors: adult patients >18 years
Jirtle 1990	Review
Kamani 1996	Unclear if one of our defined outcome measures was tested
Kamble 2006	Review
Kaste 1999	Not reporting on hepatic late adverse effects
Kazanowska 2004	Not reporting on hepatic late adverse effects
Khouri 2002	No childhood cancer survivors: adult patients >18 years
Kim 2000	No childhood cancer survivors: adult patients
Kotz 1982	Case series
Kremens 2002	Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Kudo 1996	No childhood cancer survivors
Lackner 2000	Impossible to differentiate between patients with and without potentially high‐risk treatment for hepatic late adverse effects
Lackner 2007	Not reporting on hepatic late adverse effects according to our defined outcome measures: hepatitis virus infection
Ladenstein 1997	Not reporting on hepatic late adverse effects
Leonardi 2003	Cancer treatment unclear
Leung 2000	Liver function testing in hepatitis virus positive patients
Levitt 2004	Not reporting on hepatic late adverse effects according to our defined outcome measures
Ljungman 1995	Less than 50% aged 18 years or younger
Locasciulli 1989	Less than 50% aged 18 years or younger
Locasciulli 1990a	Age of the patients unclear
Locasciulli 1990b	Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Locasciulli 1991b	Less than 50% aged 18 years or younger
Locasciulli 1993	Liver function testing in hepatitis virus positive patients
Locasciulli 1995	Review
Maggiore 1982	Not reporting on hepatic late adverse effects according to our defined outcome measures: hepatitis virus infection
Maguire 2002	Not reporting on hepatic late adverse effects
Martinez 1997	No childhood cancer survivors: adult patients >18 years
Masera 1981	Liver function testing in hepatitis virus positive patients
McBride 1976	Less than 50% aged 18 years or younger
McIntosh 1977	Less than 10 childhood cancer survivors
McKay 1996	Less than 50% aged 18 years or younger
Meadows 1992	Unclear if one of our defined outcome measures was tested
Mitrou 1990	Not reporting on hepatic late adverse effects
Moore 1995	Not reporting on hepatic late adverse effects
Morrow 1982	Not reporting on hepatic late adverse effects
Murthy 1978	Not reporting on hepatic late adverse effects
Myers 1995	Not reporting on hepatic late adverse effects according to our defined outcome measures: hepatitis virus infection; Information on liver function reported for only 1 patient
Nagasue 1979	No childhood cancer survivors: adult patients >18 years
Nagatoshi 1997	Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Neilson 1996	Age of the patients and cancer treatment unclear
O'Hara 1968	Not reporting on hepatic late adverse effects
Oeffinger 2006	Not reporting on hepatic late adverse effects
Osborne 1980	No childhood cancer survivors: adult patients >18 years
Pantoja 1975	No childhood cancer survivors: adult patients >18 years
Pao 1989	Not reporting on hepatic late adverse effects
Park 2002	Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Poussin‐Rosillo 1976	Less than 50% aged 18 years or younger
Pratt 1977	Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Pritchard 2005	Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Pui 1992	Not reporting on hepatic late adverse effects
Punyko 2005	Not reporting on hepatic late adverse effects
Puri 2006	Not reporting on hepatic late adverse effects
Ravikumara 2006	Less than 50% off treatment for 1 year or more
Reaman 1985	Not reporting on hepatic late adverse effects
Rodriguez‐Inigo 1997	No childhood cancer survivors: adult patients
Rossetti 1992	Number of patients with liver function testing unclear; Liver biopsy during first year after chemotherapy (<1 year off treatment)
Samuelsson 1999	Not reporting on hepatic late adverse effects
Sawamura 1998	Not reporting on hepatic late adverse effects
Schaison 1980	Number of patients with liver function testing unclear
Sekine 1998	Number of patients with liver function testing unclear
Sevinir 2003	Liver function testing in hepatitis virus positive patients
Shah 2004	Not reporting on hepatic late adverse effects
Silverman 1997	Not reporting on hepatic late adverse effects
Skidmore 1997	No childhood cancer survivors: adult patients
Socié 1999	Less than 50% aged 18 years or younger
Socié 2001	Not reporting on hepatic late adverse effects
Spunberg 1981	Not reporting on hepatic late adverse effects
Strasser 1999a	Less than 50% aged 18 years or younger
Strasser 1999b	Less than 50% aged 18 years or younger
Straus 1991	Not reporting on hepatic late adverse effects
Tada 1997	Liver function testing in hepatitis virus positive patients
Taylor 1997	Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Tefft 1977	Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Thomas 1988	Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Tomás 2000	Less than 50% aged 18 years or younger
Tura 1998	No childhood cancer survivors: adult patients
Uchino 1978	Not reporting on hepatic late adverse effects
Uzel 2001	Not reporting on hepatic late adverse effects
Vaidya 2000	Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
van den Ouweland 1983	Less than 50% aged 18 years or younger
Veneri 2003	No childhood cancer survivors: adult patients
Vergani 1982	Not reporting on hepatic late adverse effects according to our defined outcome measures: hepatitis virus infection; Liver biopsy at cessation of chemotherapy (<1 year off treatment)
von Schweinitz 1994	Not reporting on hepatic late adverse effects
Wasserheit 1995	Less than 50% aged 18 years or younger
Weirich 2004	Unclear if one of our defined outcome measures was tested
Wexler 1996	Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Willers 2001	Liver function testing in hepatitis virus positive patients
Wolff 2006	Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Woolfrey 1998	Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Yamada‐Osaki 1999	Liver function testing in hepatitis virus positive patients
Yang 2005	Not reporting on hepatic late adverse effects
Yang 2006	Not reporting on hepatic late adverse effects
Zimmermann 2002	Not reporting on hepatic late adverse effects: acute toxicity (<1 year off treatment)
Zittoun 1985	Less than 50% aged 18 years or younger